Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide

Journal of Medical Primatology

Volumn 36, Issue 4-5, 2007, Pages 244-253

  Emau, P ^a   Tian, B ^a   O'Keefe, B R ^b   Mori, T ^b,d   McMahon, J B ^b   Palmer, K E ^c   Jiang, Y ^a   Bekele, G ^a   Tsai, Che Chung ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Anti HIV microbicide candidate; Binding; Entry inhibitor of HIV; Griffithsin; Virucide

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBOHYDRATE BINDING PROTEIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GRIFFITHSIN; MICROBICIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; CELL FUSION; CELL TRANSFER; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; HETEROSEXUALITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PH; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; UTERINE CERVIX MUCOSA; VAGINA DISCHARGE; VAGINA MUCOSA; VAGINAL LAVAGE; VIRUS INHIBITION; VIRUS STRAIN; VIRUS TRANSMISSION;

ALGAL PROTEINS; ANIMALS; ANTI-HIV AGENTS; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; HIV INFECTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; LECTINS; MACACA NEMESTRINA; RECEPTORS, CCR5; RECEPTORS, CXCR4; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINAL DOUCHING;

HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34547109661     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2007.00242.x     Document Type: Conference Paper

References (27)

1. Andersch-Bjorkman Y, Thomsson KA, Holmen Larsson JM, Ekerhovd E, Hansson GC: Large-scale identification of proteins, mucins and their O-glycosylation in the endocervical mucus during the menstrual cycle. Mol Cell Proteomics. [Epub ahead of print] 2007; 6: 708-16.
2. Barrientos LG, Gronenborn AM: The domain-swapped dimer of cyanovirin-N contains two sets of oligosaccharide binding sites in solution. Biochem Biophys Res Commun 2002; 298: 598-602.
3. Barrientos LG, Lasala F, Delgado R, Sanchez A, Gronenborn AM: Flipping the switch from monomeric to dimeric CV-N has little effect on antiviral activity. Structure 2004; 12: 1799-807.
4. Brabin L, Roberts SA, Fairbrother E, Mandal D, Higgins SP, Chandiok S, Wood P, Barnard G, Kitchener HC: Factors affecting vaginal pH levels among female adolescents attending genitourinary medicine clinics. Sex Transm Infect 2005; 81: 483-7.
5. Castle PE, Karp DA, Zeitlin L, Garcia-Moreno EB, Moench TR, Whaley KJ, Cone RA: Human monoclonal antibody stability and activity at vaginal pH. J Reprod Immunol 2002; 56: 61-76.
6. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359-62.
7. Giomarelli B, Schumacher KM, Taylor TE, Sowder RC II, Hartley JL, McMahon JB, Mori T: Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture. Protein Expr Purif 2006; 47: 194-202.
8. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, Blanchard J, Baskin G, Cheng-Mayer C: Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 2001; 75: 1990-5.
9. Henderson HI, Hope TJ: The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection. J Virol 2006; 3: 36.
10. Kim SY, Byrn R, Groopman J, Baltimore D: Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: Evidence for differential gene expression. J Virol 1989; 63: 3708-13.
11. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, Zupancic M, Busch M, Carlis J, Wolinsky S, Haase AT: Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79: 9217-927.
12. Mori T, O'Keefe BR, Sowder RC II, Bringans S, Gardella R, Berg S, Cochran P, Turpin JA, Buckheit RW Jr, McMahon JB, Boyd MR: Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005; 280: 9345-953.
13. Oliyai R, Yuan LC, Dahl T: Kinetic studies of the degradation of oxycarbonyloxymethyl prodrug of Adefovir and Tenofovir in solution. Nucleosides Nucleotides Nucleic Acids 2001; 20: 1295-8.
14. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-8.
15. Platt EJ, Durnin JP, Kabat D: Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol 2005; 79: 4347-56.
16. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/ coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002; 99: 16249-54.
17. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A: Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42: 612-7.
18. Soderberg K, Denekamp L, Nikiforow S, Sautter K, Desrosiers RC, Alexander L: A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J Virol 2002; 76: 5803-6.
19. Temin HM, Bolognesi DP: AIDS. Where has HIV been hiding? Nature 1993; 362: 292-3.
20. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, Schmidt A, Morton WR, Gustafson KR, Boyd MR: Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004; 20: 11-8.
21. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, Gustafson KR, Boyd MR: Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003; 19: 535-41.
22. WHO/UNAIDS: Progress on Global Access to HIV Antiretroviral Therapy: A report on 3'by 5'and Beyond. 2006a.
23. WHO/UNAIDS: Report on Global AIDS Epidemic. May 2006b.
24. Willey S, Peters PJ, Sullivan WM, Dorr P, Perros M, Clapham PR: Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: Effects of viral diversity, target cell and receptor density. Antiviral Res 2005; 68: 96-108.
25. Yuan LC, Dahl TC, Oliyai R: Degradation kinetics of oxycarbonyloxymethyl prodrugs of phosphonates in solution. Pharm Res 2001; 18: 234-7.
26. Ziolkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, Vojdani F, Palmer KE, McMahon JB, Wlodawer A: Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 2006; 14: 1127-35.
27. Ziolkowska NE, Wlodawer A: Structural studies of algal lectins with anti-HIV activity. Acta Biochim Pol 2006; 53: 617-26.